AFPI KARNATAKA QUARTERLY NEWSLETTER
President’s Letter
Dear friends,
For this issue, I thought I would write on the critical role Family Medicine
physicians play along the continuum of care.
Ultimately, what do patients and families expect from the health care system?
As the theme of our Karnataka State Conference in Belagavi emphasized,
society expects the health care system to deliver RRR - the right care at the
right time for the right price. In other words,people expect trustworthy,
competent, cost effective care that is timely.
Sometimes the discourse around primary care breaks down into a hierarchy
(primary care in the community, secondary care at smaller hospitals, and
tertiary care at highly specialised referral centres) or a dichotomy - primary
care outside the hospital vs hospital based care.
Actually, to ensure the people receive RRR,ensuring the design principles of
FamilyMedicine i.e. Continuous care, ComprehensiveCare, Contextual care,
Care at first contact, andCoordinated Care, is critical.
This is only possible when the role and influence of the family physician
extend across the care Continuum from the ICU, throughInpatient Care, the
Emergency Department, theOPD of a hospital, the clinic in the
community,and the patients' home.
As FPs, it behooves us to exert our leadership and claim our due role across
the care continuum. Not doing so automatically results in the fragmentation
we lament about with its multitude of ill effects in terms of unnecessary tests,
procedures, medications, polypharmacy, lack of coordination, longer
hospitalization, poorer outcomes, and catastrophic costs.
Best wishes
Dr. Ramakrishna Prasad
President
AFPI Karnataka
Editorial Note
Lobbying and networking
There are three classes of people. One class dreams but does not act. The other class acts without
dreaming. The first one as one can see, will remain so and nothing happens. This class is also wont to
complain bitterly why and how their dreams lie shattered. The other who acts is like rudderless vehicle
with no aim and this can-do harm as they have no goal to achieve. The perfect examples are our docile
bureaucrats who act on the directions of our political leaders whose dreams are o en not directed
towards nation building, but towards short sighted personal or political gains.
The last but a very important class is that of a class of people who dream and act. I see this happening in
the present political financial scenario. What about the national primary health scene? Despite the best
efforts of some of us [ Raman Kumar and co], lot remains to be done to get the specialty of primary care
the preeminence in health care delivery that it richly deserves. Sensitizing our politicians as to how and
why of this is of paramount importance. AFPI members in general, and office bearers in particular
should start actively lobbying these functionaries at all levels, starting from the ward level up to the state
and central government level.
Developing a network with the bureaucrats and politicians, therefore is of utmost importance. Right
now, organ specialists of curative medicine, hold the sway and their influence and clout is much more
than that of generalists like family doctors. So is true of large private players in the field of health,
mostly curative health.
Thus, it is an unavoidable and very important duty that we family physicians actively engage and
impress upon the powers [read politicians and bureaucrats], the need for change and the ways to do it.
Coming to another aspect of developing and maintaining contacts [networking ]. We are social animals
and depend on each other for our mental and physical wellbeing. It may be relatives, friends and even
strangers whom we are interacting with, all are important in one way or the other, we cannot live in
isolation and be happy. More and more reports are coming from the professional and lay media as to
the importance of social interaction in preventing early death.
More than any profession social interaction and networking is important to us general practitioners.
This can be between us, our patients, and other doctors belonging to other specialties. This will help our
patients directly and us indirectly. How one can develop long lasting such relationships? Let me give
you an example. You need a second opinion and you think Dr x is the right person. You tell the patient
to go and see that doctor. You do not give a reference letter describing the reason why you are sending
the patient, your tentative diagnosis and the treatment so far given and a request for the specialist to get
back to you and the like. You have also have not told the patient to get back to you. You have
successfully terminated the social and professional interaction between you and the patient and
prevented the other doctor getting back to you. In all possibility you have lost that patient.
The right way would have been to give a note with all the particulars and ask the patient to come back
to you a er seeing the other doctor and telephone the doctor and tell him that so and so patient is
going to see him and request him to call a er seeing the patient. With this you will establish a 3-way
relationship. Over years your patient will come to know you and so will be the doctor and vice versa
and a useful relationship is built up. This may last or may not is a different matter. Occasionally a
physical meeting with the specialist doctor or your own FP colleague will further strengthen this
networking.
2
This relationship based on mutual interest and respect will help us as well as our patients and the other
doctor whose help you have sought.
Dr B C Rao
AFPI-NEWS
Celebrating 4 Months of Continuous
Learning and Collaboration
Greetings from AFPI Karnataka! We are thrilled
to share the latest updates on our Continuing
Medical Education (CME) initiatives, marking a
successful journey of collaborative learning over
the past four months. Our focus has been on
providing highly relevant sessions tailored for
general practitioners, fostering interdisciplinary
learning, engagement in primary care, and
creating networking opportunities for medical
professionals across Karnataka.
Recent CME Highlights:
October Session: Infectious Disease
Management in Various Conditions
In collaboration with RXDX Samanvay Clinic,
AFPI organized a compelling CME session on
infectious disease management in October. The
session delved into crucial topics, including the
importance of adult vaccination in diabetes and
other chronic diseases, combating infections in
rheumatology, oral infections in diabetes,
dermatological infections and their
management, the significance of pediatric
vaccination, GI infections in children, and their
management, as well as URTI and LRTI in
children. The CME received positive feedback
from delegates, affirming its value in enhancing
knowledge and skills.
November Workshop: AI Unmasked -
Harnessing the Future of Medicine
AFPI, in association with Bangalore Baptist
Hospital, conducted a workshop in November
titled "AI UNMASKED - How Doctors Can
Harness the Future of Medicine." This insightful
workshop empowered participants to seamlessly
integrate AI, with a special focus on ChatGPT,
into their clinical practice and autonomous
learning endeavors. The session covered
essential aspects such as prompt cra ing,
diagnostic decision-making, investigation
selection, pharmacological treatment guidance,
non-pharmacological intervention
recommendations, and referral letter
composition. Additionally, participants learned
to develop patient education materials with the
assistance of AI/ChatGPT. The workshop
provided valuable insights into the evolving
landscape of healthcare technology.
As we reflect on these enriching experiences,
AFPI Karnataka remains committed to
advancing medical education, promoting
collaboration, and fostering continuous
learning. Stay tuned for more engaging
initiatives in the upcoming quarters!
Warm regards,
Dr Shalini Chandran
drshalinichandan@gmail.com
3
Enterprise and Risk-Taking in Family Practice : Through a personal Journey
Introduction:
Family practice, o en considered the backbone
of healthcare, plays a pivotal role in ensuring the
well-being of individuals and communities. In
the dynamic landscape of healthcare, the role of
family physicians has evolved beyond the
traditional confines of clinics and hospitals. The
field requires a unique blend of enterprise and
risk-taking while navigating the complexities of
patient care, evolving medical landscapes, and
the challenges posed by the dynamic nature of
the healthcare industry. Embarking on a
journey from a thriving career in the armed
forces to establishing a private family practice in
the bustling city of Bangalore was not just a
career move for me; it was a profound personal
transformation. In this reflection on my unique
journey, I aim to shed light on the intricate
dance between enterprise and risk-taking in the
field of family medicine, a field that I now call
Home.
The Decision to Take the Leap: The
Entrepreneurial Spirit in Family Practice
Leaving the structured environment of the
armed forces to embrace the uncertainties of
private practice was not a decision made lightly.
It involved a thorough evaluation of my skills,
passion for patient care, and a vision for a more
personalized approach to healthcare. The shi
from a salaried position to the entrepreneurial
venture of running a private practice brought
with it a myriad of challenges and opportunities.
Unlike other vocations in medical profession,
being a family physician meant not just treating
patients but also managing staff, finances, and
adopting innovative technologies to run a
practice as a profitable business.
Calculated Risk in Enterprise:
The cornerstone of any successful enterprise lies
in the ability to take calculated risks. In the
context of family practice, this translates to
understanding the unique needs of the
community, identifying gaps in healthcare
services, and envisioning innovative solutions.
My decision to establish a private practice in the
suburb of a metro city was rooted in a
comprehensive market analysis that revealed a
growing demand for personalized,
patient-centric healthcare services. As family
practitioners, we are accustomed to making
critical decisions with incomplete information.
Diagnosing complex conditions and developing
treatment plans require a delicate balance
between potential benefits and inherent risks.
This ability to make informed decisions in the
face of uncertainty is not just a skill; it's a
hallmark of a successful family practitioner.
Financial Considerations and Sustainability:
The financial aspect of running a private
practice cannot be overlooked. The initial
investment in setting up the clinic, acquiring
equipment, and hiring staff requires a judicious
approach. Diversifying revenue streams,
optimizing operational efficiency, and
maintaining a balance between quality care and
financial sustainability are critical elements in
mitigating the financial risks associated with
family practice entrepreneurship. All I can say at
this juncture is that setting up one's own medical
practice doesn't always necessitate a massive
capital investment, and there are ways to
navigate the financial landscape judiciously.
Building a Patient-Centric Practice:
One of the primary risks involved in family
practice entrepreneurship is the need to
differentiate oneself and standing out in a
saturated market. Why patients choose one
doctor over the other needs a careful analysis.
By focusing on a patient-centric approach, I
aimed to establish a practice that went beyond
the conventional transactional nature of
healthcare. Building trust and rapport with
patients fostering a compassionate and
communicative doctor-patient relationship was
my primary focus. Staying connected with
patients during difficult times like COVID
4
pandemic has immensely contributed to the
sustainability and growth of my practice.
Adapting to Technological Advancements:
Staying current with technological
advancements was a significant challenge.
Embracing innovation became not only
essential for improving patient outcomes but
also for the very survival of the practice.
Electronic health records, telemedicine, and
other digital tools transformed the way I
delivered care. By investing in and adapting to
these technologies, practitioners can streamline
processes, enhance communication, and
provide more efficient and patient-centered
services.
Building Trust in the Community:
Establishing trust within the community is a
gradual process that requires consistent effort
and a genuine commitment to patient
well-being. By actively participating in
community outreach programs, collaborating
with local organizations, and maintaining
transparent communication, I aim to foster a
sense of trust and credibility, essential for the
long-term success of the practice.
Navigating Healthcare Policies and
Regulations:
The ever-evolving landscape of healthcare
policies and regulations presents another
challenge for family practitioners. Staying
compliant with changing laws while maintaining
a focus on patient care requires a nuanced
approach. Navigating insurance requirements,
reimbursement structures, and government
mandates demands a level of adaptability and
resilience that is essential for success in family
practice.
Conclusion:
The journey from a military career to family
practice entrepreneurship in Bangalore has been
a rewarding experience, filled with challenges
and triumphs. Navigating the delicate balance
between enterprise and risk-taking in family
medicine required a holistic approach,
encompassing market analysis, technological
integration, financial prudence, and an
unwavering commitment to patient care. In the
era of healthcare corporatization driving up
costs, family physicians turned entrepreneurs
become champions of accessible, compassionate
care. Our personalized approach not only
shapes the future of healthcare but provides a
crucial alternative to the impersonal systems. As
family physicians continue to evolve as
entrepreneurs, they not only play a pivotal role
in shaping the future of healthcare delivery but
also offer a personalized and compassionate
alternative in the ever-changing landscape of
medicine.
Col(Dr) Mohan Kubendra
mohankubendra@gmail.com
5
Clinical inquiry
What is the evidence-based recommendation for treatment of post viral cough?
Evidence based answer:
There are many pathogenic factors that may
contribute to cause of post infectious cough like
post viral airway inflammation leading to
bronchial hyper-responsiveness, mucus
hyper-secretion and impaired mucociliary
clearance, UACS, asthma, GERD, and the like.
Judge which factors are most likely to be
provoking cough before considering therapy.
(Expert opinion)
However, most Post infectious cough usually
resolves on its own. Data for evidence of benefit
from bronchodilators, ICS, Ipratropium
bromide is limited.
Bronchodilators: Some patients with post viral
cough without Upper airway cough syndromes
like PND have transient airway hyper-reactivity
that is associated with a positive methacholine
challenge test in research studies. Albuterol may
be of benefit to such patients, although data is
limited. *
In patients with post viral cough who have no
evidence of airway hyper-reactivity, inhaled
ipratropium has been reported to produce
improvement in the cough **
Discussion:
Definition
Coughs that persist a er a common cold or
other upper respiratory infection are called
post-infectious or post-viral coughs. They can
linger for three to eight weeks a er a viral
infection.
Theories about what causes it:
● Postnasal drip secondary to persistent
rhino sinus inflammation
● Inflammation of airways: Direct effect of
the viral infection to increase bronchial
reactivity
● Increased cough receptor sensitivity
● When postinfectious cough emanates
from the lower airway, this is o en
associated with the accumulation of an
excessive amount of mucus
hypersecretion
● GERD because of vigorous coughing
Evidence Summary
ACCP EB clinical practice guidelines for post
infectious cough are based on data using
PubMed search for “cough” “post infectious
cough” “post viral cough” “pertussis” and
“whooping cough”. ACCP recommends initial
treatment based on clinical assessment of cause
of cough like Postnasal drip, airway
hypersensitivity, hypersecretion.
Bronchodilators versus placebo: One RCT6 of
92 patients (cough duration 3 to 4 weeks) using a
combination of nebulized salbutamol and
ipratropium found the proportion with ongoing
cough at day 10 was 37% versus 69% placebo
(number needed to treat=3). There was no
difference at day 20 (both >80% resolved).
- Limitations: Studies were small, used
nonvalidated cough scores, and recorded
multiple outcomes.
In a systematic review and meta-analyses of
randomized clinical trials published in British
journal of General practice, six eligible RCTs
including 724 patients were identified. These
assessed montelukast, salbutamol plus
ipratropium bromide, gelatine, fluticasone
propionate, budesonide, and nociception opioid
1 receptor agonist and codeine. Five studies
reported effects on various cough severity scores
at various timepoints. No treatment option was
6
associated with a clear benefit on cough
recovery or other patient-relevant outcomes in
any of the studies or in meta-analyses for cough
outcomes at 14 days and 28 days. Reported
adverse events were rather mild and reported
for 14% of patients across all treatments.
Conclusion
Evidence on treatment options for subacute
cough is weak. There is no treatment showing
clear patient-relevant benefits in clinical trials.
In a study published in CHEST, among 14 such
patients in one report, 12 had clinical
improvement with administration of 320 mcg
of inhaled ipratropium, and of these, five had
complete resolution of cough)
To summarize, most post infectious cough gets
better on its own. ACCP clinical practice
guidelines discuss treatment based on clinical
assessment for cause of cough as discussed
above. Options for treatment may include
decongestants, bronchodilators, ipratropium
inhalation. It is important in a subacute cough to
distinguish between Post infectious cough and
other entities that cause subacute cough like
cough variant asthma, pertussis and treat those
Case Report
Myocardial Bridge
Mr P a 78 years old well controlled diabetic and
hypertensive came with complaints of
breathlessness on excretion and tightness in the
chest. His resting ECG showed minimal changes
in chest leads. A cardiology referral resulted in
doing Echo and Angiogram. The report came as
presence of Myocardial bridge in the middle
portion of anterior descending coronary.
Advised medical management.
appropriately including use of antibiotics for
pertussis. But routine use of antibiotics is not
beneficial in subacute cough not due to bacterial
infections.
References:
*Chronic cough due to asthma: ACCP
evidence-based clinical practice guidelines.
Chest. 2006;129(1 Suppl):75S.).
** Postinfectious cough: ACCP evidence-based
clinical practice guidelines.
Braman SS Chest. 2006;129(1 Suppl):138S
British journal of General Practice: Treatments
for subacute cough in primary care: systematic
review and meta-analyses of randomized
clinical trials
Canadian Family Physician-Tools for practice
Dr Preeti Aski
sonypreeti@gmail.com
Discussion
Normally Coronary arteries lie in the sulci on
the surface of the heart. When one or more
arteries, in varying length lie inside the
musculature, the overlying tissue is called the
myocardial bridge. This anomaly is present
since birth and is estimated as high as 25% of the
population going by the autopsy studies. Earlier
this was thought to be benign but with advanced
imaging studies and varying symptoms at
presentation it is now not considered as benign
as it was thought and o en need either
pharmacological or surgical intervention.
7
During systole there is compression of the heart
muscle which squeezes the heart muscle which
in turn compresses the buried segment of the
artery, narrowing the lumen thus impeding the
flow. In diastole the heart muscle relaxes quicker
than the arterial wall thus to some extent the
lumen remains narrow. Depending on where
this segment lies and the length, the symptoms
vary. And if it is some small vessel or where it is
very short there may be no symptoms at all.
Where as if it is present in anterior descending
artery [o en], the symptoms can be severe.
When it is presented in the young without any
other known predisposing cause like family
history, high lipid levels and the like, one must
exclude myocardial bridging as a likely cause as
routine testing like ECG may or may not reveal
any abnormality. High degree of suspicion
especially when a young and otherwise fit
person presents with symptoms will help in the
diagnosis and treatment. For further
information as to the classification, management
protocol, please refer to the link given below
Journal of the American College of Cardiology
https://www.jacc.org › doi › j.jacc.2021.09.8
Dr B C Rao
Badakere.rao@gmail.com
Infective endocarditis in elderly – a case series
Background
Infective endocarditis (IE) is a rare but severe
disease with high mortality and morbidity rates
despite significant advances. Although
predominant in younger population; prevalence
of IE has increased among elderly population in
recent years. Incidence of IE is especially higher
in patients above 70 years of age. Estimated
annual incidence of IE is 3 to 10 cases per
1,00,000, with wide regional variations. The
wide variabilities in clinical presentation and
difficulties in treatment decision making poses a
significant challenge in management of elderly
population with IE.
With this case series we aim to describe the
clinical profile of IE in elderly and to understand
the therapeutic challenges in elderly with IE.
CASE 1
CASE 2
History
68-year-old female -
High grade fever, arthralgia,
generalized fatigue
,significant weight loss x 4 months
Slow speech and response x 2 days
A 69-year-old female –
High grade fever ,headache and jaw pain x 3
months
Complicat
Acute non hemorrhagic infarct
Nil
ions
Predisposi
ng factors
Nil
K/c/o HTN x 3 years
H/o recent tooth extraction
Examinati
Febrile, Pallor(+)
Febrile, Pallor (+)
on
A pansystolic murmur Splenomegaly
A pansystolic murmur Splenomegaly
8
Investigati
Anemia, Blood cultures: Streptococcus
Anemia,
on
sanguinis 2D-Echo: Moderate-severe
mitral regurgitation with a 14 x 5 mm
vegetation on the posterior mitral
leaflet
Blood cultures : no growth
2D Echo: severe mitral regurgitation with
vegetations of 5 x 9mm on anterior mitral
leaflet
Treatment
IV antibiotics (Ce riaxone and
Gentamicin) for 6 weeks+
IV antibiotics (Ce riaxone and Gentamicin) for
6 weeks
Challenge
Decision making on surgical
Getting IV access
s
intervention
Impaired renal parameters
Continuous monitoring
Review
The causative organisms, clinical presentation,
risk factors of IE are all different in elderly
population with respect to the general
population. In the second case scenario, patient
had a predisposing factor for occurrence for IE,
whereas in the first case scenario, patient was
devoid of any predisposing factors. This
emphasizes on the fact of acquiring more
knowledge and need for further studies to
understand more about the possibility of
occurrence of the disease even in absence of risk
factors. This being an unresolved problem along
with challenges like vague presentations and
older age with neglected symptoms itself o en
results in delayed diagnosis and treatment of IE
which in effect results in poor outcomes.
No specific treatment guidelines are currently
available for IE in elderly. This poses multiple
challenges in management of the same. One
being the choice of opting between medical
management vs surgical management. Studies
have shown that there is an independent
association of geriatric parameters like age,
comorbidities, function, cognition, nutrition
with treatment outcomes. Hence, a
comprehensive geriatric assessment would
greatly help in decision making regarding
medical /surgical management.
A lot of studies show that undergoing surgery in
elderly population with IE even when indicated
(Case 1) has much greater risks than when done
in younger population. However, a few trials
have shown to bring better outcomes from
surgery for patients with IE, provided, patients
have normal blood parameters.
Medical management is the most widely used
and recommended choice of treatment for IE in
elderly. This includes IV Antibiotics for
prolonged duration which results in prolonged
hospital stay.This itself poses a challenge in
elderly patients as this can result in drug related
toxicity, hospital associated infections and even
worsening of frailty among elderly especially
due to reduced activity, mobility and
malnutrition while being in hospital for
prolonged period.
9
GENERAL POPULATION
ELDERLY POPULATION
Fever
High grade fever
Low grade fever
Malaise
Less common
More common
Anorexia
Less common
More common
Weight loss
Less common
More common
Immune
mediated
More common
Less common
phenomenon
Sex
M > F
F > M
Risk factors
IV drug use Community acquired
infection
Comorbidities (Cardiac
)/Nosocomial
infections/Dental
procedures/Prosthetic valves
Most common causative
Staphylococcus
aureus
>
Enterococcus
agent
Streptococcus
Complications
Less
More
Ease of treatment
Easier
(Surgery > Medical)
Difficult
Summary
● IE is a rare, yet severe disease with fatal
outcomes
● They can come with variable clinical
presentations especially among elderly.
● Diagnostic clinical triad – Pallor, murmur,
splenomegaly — which helps in quick
OPD assessment.
● Comprehensive geriatric assessment
helps in making optimal management
decisions (Medical Vs Surgical)
● More studies are to be done on age
specific management and age specific
A case of Infectious Mononucleosis
A 15-year-old girl presented with low grade
fever, weakness and back pain since a week. She
also had nausea and yellowish discoloration of
the conjunctiva and was passing dark yellow
urine in the last two days. Nothing significant in
the past history . No known drug allergies.
Clinically vitals were stable. Throat was
congested, chest and abdomen evaluation were
guidelines are to be established to
improve compliance,reduce side effects,
bring about better outcomes, and thereby
improve quality of life among elderly
population with IE.
Namiya
1
Jose ,
Hemavati
2
Dasappa
, Sanjiv
Lewin , G D Ravindrran 4
3
1 Junior Resident, 2 Assistant Professor,
3 Professor, 4 Professor, Department of Family
medicine, St Johns Medical College & Research
Institute, Bengaluru
normal. A presumptive diagnosis of Viral
Hepatitis was made. She was administered a pint
of normal saline with multivitamins. Routine
blood tests were ordered, CBC, LFT, KFT and
HAV, HEV were done. Dengue and typhoid tests
were negative. Labs showed high WBC count
11,350 cells /cmm, high lymphocyte count 68.3%,
direct bilirubin was high at 4.1 mg /dl, indirect
bilirubin was at 0.69 mg /dl, AST 229 U/L and
10
ALT 290U/l . Rest of the laboratory tests came
negative. USG abdomen and pelvis showed
coarse hepatic echotexture and mild
splenomegaly. Subsequently in the evening ,
her throat pain became very severe and cervical
lymph nodes were palpable and a decision was
reached to shi her to hospital in view of
symptoms and altered liver function.
At the hospital a diagnosis of infectious
mononucleosis was made and patient was
administered IV acetyl cysteine infusion to
bring down the high liver enzymes. She was
given symptomatic treatment. Epstein Barr
Virus antibody viral capsid antigen IGM turned
out to be positive and the patient was discharged
a er two days as her condition was stable.
Daycare treatment at the clinic.
Since she continued to have severe throat pain ,
she was shown to an ENT specialist who
diagnosed the case as acute membranous
tonsillitis. WBC count had increased to 19,000
cells/cmm, lymphocytes continued to be high
68%, CRP was 11mg/dl. It was decided to treat
her with injectable antibiotics in view of the
high WBC counts and thick membrane on both
tonsils. She was having excruciating throat pain
and was unable to even swallow water. She was
administered ce riaxone 1gm twice a day and
amikacin 500 mg twice a day x 3 days. She was
treated with paracetamol and voveran for relief
from throat pain. Despite medications , patient
still had extreme discomfort from throat pain.
She was unable to sleep in the night due to pain.
At this point, she was given one dose of
dexamethasone 4 mg intramuscularly. With this,
the pain came down. Over the course of next 3
days , symptoms reduced and she was switched
to tab Ce um 500 mg twice a day x 4 days a er
food. Throat swab returned no growth. Repeat
CBC and LFT done a er 10 days had returned
to normal limits.
Probable source of infection : Used friend’s lip
balm.
Discussion : I had missed the diagnosis at the
first instance due to the high liver enzymes.
Infectious mononucleosis occurs in mainly
adolescents and young adult groups. The patient
presented with fever , throat pain, fatigue and
associated cervical lymphadenopathy, all
classical symptoms of the disease. Rash can also
be seen which can be aggravated or can occur if
Amoxycillin is administered. This is an
important aspect which needs to be considered
in practice. The high WBC count ,the high
Lymphocyte count , elevated aminotransferases
and EBV antibodies are tests which would help
to clinch diagnosis. Additional tests include a
throat swab to rule out streptococcal infection,
which was done in this case and turned out to be
negative. Infectious Mononucleosis and bacterial
tonsillitis are a rare mix. Whether the tonsillitis
was a part of infectious mononucleosis or
tonsillitis perse was difficult to gauge and the
ENT specialist could not ascertain the cause too.
Most EBV infections require only symptomatic
treatment. However, corticosteroids may be
used if airway is compromised. We used a dose
of steroids to relieve the pain. Though
symptoms may persist for a couple of weeks the
prognosis is generally good for most patients,
fatigue may persist in 10% of individuals . In our
group practice over the past 15 years, though we
have seen multiple suspected cases of infectious
mononucleosis, the monospot and EB virus tests
turned out to be negative. This could be
attributed to Infectious mononucleosis being
caused by other viruses. This was the first such
case seen by our group and hence we decided to
present it.
Dr C M A Belliappa
Belliappa.cma@rxdx.in
11
What is new?
The field of family medicine is constantly
evolving, making it challenging for the
interprofessional healthcare team to stay up to
date with recent developments. This article
covers key advancements in the field that may
have important implications for clinical
practice.
This symptom signals UTI in 83% of
cases
A bacterial infection of the bladder and its
related structures is known as a urinary tract
infection (UTI). When it is uncomplicated, it
may be referred to as a "lower" UTI or
cystitis. [1]
pathogens, with the most common being
gram-negative bacteria such as Escherichia
coli. [2] Women are at greater risk of developing a
UTI compared with men, because of the shorter
distance between the bladder and external part
of the body. While men may suffer from UTIs
less frequently than women, the infection tends
to be more complicated. [3]
The infection can be caused by various
Topline:
Dyspareunia (painful sexual intercourse) is a
major indicator of urinary tract infections, being
present in 83% of cases. The symptom is
especially accurate at identifying UTIs in
non-menopausal women, researchers have
found. [4]
Methodology:
Dyspareunia is a common symptom of UTIs,
especially in premenopausal women, but is
rarely inquired about during patient evaluations,
according to researchers from Florida Atlantic
University.
In 2010, the researchers found that among 3000
of their female Latinx patients ages 17 to 72 years
in South Florida, 80% of those with UTIs
reported experiencing pain during sexual
intercourse.
Since then, they have studied an additional 2500
patients from the same population.
Take away:
● Among all 5500 patients, 83% of those
who had UTIs experienced dyspareunia.
● 80% of women of reproductive age with
dyspareunia had an undiagnosed UTI.
● During the perimenopausal and
postmenopausal years, dyspareunia was
more o en associated with genitourinary
syndrome than UTIs.
● 94% of women with UTI-associated
dyspareunia responded positively to
antibiotics.
In Practice:
"We have found that this symptom is extremely
important as part of the symptomatology of
UTI [and is] frequently found along with the
classical symptoms," the researchers reported.
"Why has something so clear, so frequently
present, never been described? The answer is
simple: Physicians and patients do not talk about
sex, despite dyspareunia being more a clinical
symptom than a sexual one. Medical schools
and residency programs in all areas, especially
in obstetrics and gynecology, urology, and
psychiatry, have been neglecting the education
of physicians-in-training in this important
aspect of human health. In conclusion, this is
[proof] of how medicine has sometimes been
influenced by religion, culture, and social norms
far away from science."
Source:
The data were presented at the 2023 Menopause
Meeting of the North American Menopause
Society. The study was led by Alberto
Dominguez-Bali, MD, from Florida Atlantic
University, Boca Raton, Florida. [4]
Limitations:
The study authors report no limitations.
12
Does an elevated TSH value always
require therapy?
Hypothyroidism is a common endocrine
disorder, estimated to impact 10% of the world’s
population. [5] It is characterized by a deficiency
in thyroid hormone and may be caused by a
severe deficiency in iodine or autoimmunity in
iodine-saturated areas (more frequent).
Symptoms of hypothyroidism are o en
nonspecific, affecting multiple organ systems;
most commonly, patients may experience an
intolerance to cold climates, fatigue, and
constipation. [6] The aim of treatment is to
restore thyroid hormone levels using
medication. [7] The mainstay of treatment is
levothyroxine, [6] a synthetic version of the
hormone thyroxine (ie, the thyroid hormone,
also known as T4). [8]
Indeed, thyroxine and L-thyroxine are 2 of the
10 most frequently prescribed medicinal
products. "One large health insurance company
ranks thyroid hormone at fourth place in the list
of most-sold medications in the United States. It
is possibly the second most prescribed
preparation," said Joachim Feldkamp, MD, PhD,
director of the University Clinic for General
Internal Medicine, Endocrinology, Diabetology,
and Infectious Diseases at Central Hospital,
Bielefeld, Germany, at the online press
conference for the German Society of
Endocrinology's hormone week.
The preparation is prescribed when the thyroid
gland produces too little thyroid hormone. The
messenger substance thyroid-stimulating
hormone (TSH) is used as a screening value to
assess thyroid function. An increase in TSH can
indicate that too little thyroid hormone is being
produced. [9]
"But this does not mean that an underactive
thyroid gland is hiding behind every elevated
TSH value," said Feldkamp. Normally, the TSH
value lies between 0.3 and 4.2 mU/L.
"Hypothyroidism, as it's known, is formally
present if the TSH value lies above the upper
limit of 4.2 mU/L," said Feldkamp.
Check Again
However, not every elevated TSH value needs to
be treated immediately. "From large-scale
investigations, we know that TSH values are
subject to fluctuations," said Feldkamp.
Individual measurements must therefore be
taken with a grain of salt and almost never
justify a therapeutic decision. Therefore, a
slightly elevated TSH value should be checked
again 2 to 6 months later, and the patient should
be asked if they are experiencing any
symptoms. [10]
value normalized at the second checkup without
requiring any treatment," Feldkamp explained.
"In 50% to 60% of cases, the TSH
The TSH value could be elevated for several
reasons:
Fluctuations depending on the time of day. [11] At
night and early in the morning, the TSH value is
much higher than in the a ernoon. An acute
lack of sleep can lead to higher TSH values in
the morning.
Fluctuations depending on the time of year. In
winter, TSH values are slightly higher than in
the summer owing to adaptation to cooler
temperatures. Researchers in the Arctic, for
example, have significantly higher TSH values
than people who live in warmer regions. [12,13]
Age-dependent differences. Children and
adolescents have higher TSH values than adults
do. The TSH values of adolescents cannot be
based on those of adults because this would lead
to incorrect treatment. In addition, TSH values
increase with age, and slightly elevated values
are initially no cause for treatment in people
aged 70 to 80 years. [14] Caution is advised during
treatment, because overtreatment can lead to
cardiac arrhythmias and a decrease in bone
density.
Sex-specific differences. The TSH values of
women are generally a little higher than those in
men. [14]
Obesity. In obesity, TSH increases and o en
exceeds the normal values usually recorded in
persons of normal weight. The elevated values
do not reflect a state of hypofunction, but rather
the body's adjustment mechanism. If these
13
patients lose weight, the TSH values will drop
spontaneously. Slightly elevated TSH values in
obese people should not be treated with thyroid
hormones. [15]
The nutritional supplement biotin (vitamin H or
vitamin B7), which is o en taken for skin, hair,
and nail growth disorders, can distort measured
values. In many of the laboratory methods used,
the biotin competes with the test substances
used. As a result, it can lead to falsely high and
falsely low TSH values. At high doses of biotin
(eg, 10 mg), there should be at least a 3-day
pause (and ideally a pause of 1 week) before
measuring TSH. [16]
Hasty Prescriptions
"Sometimes, because of the assumption that
every high TSH value is due to sickness-related
hypothyroidism, thyroid hormones can be
prescribed too quickly," said Feldkamp. This is
also true for patients with thyroid nodules due
to iodine deficiency, who are o en still treated
with thyroid hormones.
"These days, because we are generally an
iodine-deficient nation, iodine would potentially
be given in combination with thyroid
hormones, but not with thyroid hormones
alone. There are lots of patients who have been
taking thyroid hormones for 30 or 40 years due
to thyroid nodules. That should be reviewed,"
said Feldkamp.
When to Treat?
Feldkamp does not believe that standard
determination of the TSH value is sensible and
advises that clinicians examine patients with
newly occurring symptoms, such as excess
weight, impaired weight regulation despite
reduced appetite, depression, or a high need for
sleep.
If there are symptoms, the thyroid function
must be clarified further. "This includes
determination of free thyroid hormones T3 and
T4, detection of antibodies against autologous
thyroid tissue such as TPO-Ab [antibody against
thyroid peroxidase], TG-Ab [antibody against
thyroglobulin], and TRAb [antibody against
TSH receptor], and ultrasound examination of
the metabolic organ," said Feldkamp.
Autoimmune-related hypothyroidism
(Hashimoto thyroiditis) is the most common
cause of an overly high TSH level.
Treatment should take place in the following
situations
[17]
:
● In young patients with TSH values > 10
mU/L;
● In young (< 65 years) symptomatic
patients with TSH values of 4 to < 10
mU/L;
● With elevated TSH values that result from
thyroid surgery or radioactive iodine
therapy;
● In patients with a diffuse enlarged or
severely nodular thyroid gland; and
● In pregnant women with elevated TSH
values.
14
Association between sleep quality and
benign prostate hyperplasia among
middle-aged and older men in India
BMC Public Health volume 23,
Article number: 1147 (2023)
Abstract
Background
The association between sleep quality and
benign prostate hyperplasia (BPH) has rarely
been studied. The aim of this study was to
examine the relationship between sleep quality
and BPH among middle-aged and older men in
India.
Methods
This study used data from men over 45 years
old in Wave 1 (2017–2018) of the Longitudinal
Aging Study in India (LASI). Benign prostate
hyperplasia was self-reported, and sleep
symptoms were assessed using five questions
modified from the Jenkins Sleep Scale. A total of
30,909 male participants were finally included.
Multivariate logistic regression analysis,
subgroup analysis, and interaction tests were
performed.
Results
Total 453 (1.49%) men reported benign prostatic
hyperplasia and have higher sleep quality score
(9.25 ± 3.89 vs. 8.13 ± 3.46). The results revealed
that the sleep quality score and risk of benign
prostatic hyperplasia were significantly
correlated a er adjusting for all confounding
factors (OR:1.057, 95% CI: 1.031–1.084, p < 0.001].
A er dividing people into four groups based on
the quartile of sleep quality scores, compared
with the first quartile group, the third quartile
group was 1.32 times, and the fourth quartile
group was 1.615 times more likely to develop
benign prostate hyperplasia. A significant
interaction effect of alcohol consumption was
observed. (p for interaction < 0.05).
Conclusion
Worse sleep quality was significantly associated
with a higher incidence of benign prostatic
hyperplasia among middle-aged and older
Indian men. A further prospective study is
needed to clarify this association and explore
potential mechanisms.
15
Adolescents' acute care use for eating
disorders has risen
During the COVID-19 pandemic, a rise in eating
disorders was observed among children and
young people. However, trends among adults
are yet to be elucidated. In order to determine
the rate of emergency department (ED) visits
and hospitalizations for eating disorders and
adolescents, researchers conducted a repeated
cross-sectional study that examined
population-based data from January 2017
through August 2022. [18]
They found that ED visits and hospital
admissions for eating disorders increased
significantly among adolescents during the
COVID-19 pandemic. ED visits increased by
121% above expected levels, and hospital
admissions increased by 54% above expected
among patients aged 10 to 17 years during the
pandemic.
"We are hoping this study continues to heighten
awareness of the importance of eating disorders,
and also to bolster support for eating disorder
programs so that we can adequately care for
patients and address the increasing demand for
treatment and services," lead author Alene
Toulany, MD, an adolescent medicine specialist
and researcher at the Hospital for Sick Children
in Toronto, told Medscape Medical News.
The study was published in the Canadian
Medical Association Journal. [18]
"A Pressing Concern"
The researchers used linked health
administrative databases that included all
patients in Ontario who were eligible for the
Ontario Health Insurance Plan, which is publicly
funded. They compared observed and expected
rates of ED visits and hospitalizations for eating
disorders between a prepandemic period
(January 1, 2017, to February 29, 2020) and a
pandemic period (March 1, 2020, to August 31,
2022). The researchers examined the following 4
age categories: adolescents (ages 10 to 17 years),
young adults (ages 18 to 26 years), adults (ages 27
to 40 years), and older adults (ages 41 to 105
years).
Among adolescents, the observed rate of ED
visits during the 30 pandemic months studied
was 7.38 per 100,000 population, compared with
3.33 per 100,000 before the pandemic
(incidence rate ratio [IRR], 2.21). The rate of ED
visits among young adults increased by 13%
above the expected rate. It reached 2.79 per
100,000, compared with 2.46 per 100,000 in the
prepandemic period (IRR, 1.13). Among older
adults, ED visits increased from 0.11 per 100,000
in the prepandemic period to 0.14 per 100,000
in the pandemic period (IRR, 1.15). The rate of
ED visits among adults remained approximately
the same.
The rate of hospital admissions among
adolescents increased by 54% above the expected
rate during the pandemic. The observed rate of
hospital admissions before the pandemic was
5.74 per 100,000, vs 8.82 per 100,000 during the
pandemic (IRR, 1.54). Hospital admissions
remained stable or decreased for the other age
groups.
"Eating disorders have increased globally in
children and adolescents during COVID," said
Toulany. "There are a number of risk factors
contributing to this pandemic rise, including
isolation, more time on social media, decreased
access to care (as many in-person services were
not available due to the pandemic), as well as
fear of getting infected. All of these could
contribute to an increased risk of developing an
eating disorder or of making an existing one
worse."
Regardless of the cause, more investment in
eating disorders research and eating disorder
programs for adolescents and adults is needed,
she said. "The pandemic served as a catalyst,
because it started to shed light on the prevalence
of eating disorders, especially in young people.
But it's very important that we recognize that
this has been a long-standing issue and a
pressing concern that has been consistently
overlooked and underfunded," said Toulany.
Surging Eating Disorders
Commenting on the findings for Medscape,
Victor Fornari, MD, director of child and
adolescent psychiatry at Zucker Hillside
Hospital/Northwell Health in Glen Oaks, New
16
York, said, "Our experience in the United States
parallels what is described in this Canadian
paper. This was a surge of eating disorders the
likes of which I had not experienced in my
career." Fornari did not participate in the current
study.
"I've been here for over 40 years, and the
average number of our inpatients in our eating
disorder program has been 3 to 5 and about a
dozen patients in our day clinic at any one time.
But in the spring of 2020, we surged to 20
inpatients and over 20 day patients," Fornari
said.
"We can speculate as to the reasons for this," he
continued. "Kids were isolated. School was
closed. They spent more time on social media
and the internet. Their sports activities were
curtailed. There was anxiety because the
guidance that we were all offered to prevent
contagion was increasing people's anxiety about
safety and danger. So, I think we saw dramatic
rises in eating disorders in the same way we saw
dramatic rises in anxiety and depression in
adolescents, as well."
Fornari also cited social media as an important
contributing factor to eating disorders,
especially among vulnerable teenagers. "Many
of these vulnerable kids are looking at pictures
of people who are very thin and comparing
themselves, feeling inadequate, feeling sad.
Social media is one of the reasons why the rates
of psychopathology amongst teens has
skyrocketed in the last decade. The surgeon
general recently said we should delay access to
social media until age 16 because the younger
kids are impressionable and vulnerable. I think
there is wisdom there, but it is very hard to
actually put into practice."
Worsening Mental Health
"I thought this was very relevant research and an
important contribution to our understanding of
eating disorders during pandemic times," said
Simon Sherry, PhD, professor of psychology
and neuroscience at Dalhousie University in
Halifax, Nova Scotia. "It also dovetails with my
own experience as a practitioner." Sherry was
not involved in the research.
The pandemic has been difficult for people with
disordered eating for many reasons, Sherry said.
"There was a massive disruption or 'loss of
normal' around food. Restaurants closed,
grocery shopping was disrupted, scarcity of food
occurred, hoarding of food occurred. That
meant that eating was difficult for all of us, but
especially for individuals who were rigid and
controlling around the consumption of food. In
this COVID era, you would need flexibility and
acceptance around eating, but if you had a
narrow range of preferred foods and preferred
shopping locations, no doubt the pandemic
made this a lot worse."
Certain forms of disordered eating would be
much more likely during the pandemic, Sherry
noted. "For example, binge eating is o en
triggered by psychological, social, and
environmental events," and those triggers were
abundant at the beginning of the pandemic.
Boredom, anxiety, depression, stress, loneliness,
confinement, and isolation are among the
triggers. "COVID-19-related stress was and is
very fertile ground for the growth of emotional
eating, binge eating, or turning to food to cope.
Eating disorders tend to fester amid silence and
isolation and inactivity, and that was very much
our experience during the lockdown phase of
the pandemic," he said.
Sherry agrees with the need for more funding
for eating disorders research. "We know in
Canada that eating disorders are a very
important and deadly issue that is chronically
underfunded. We are not funding disordered
eating in proportion to its prevalence or in
proportion to the amount of harm and
destruction it creates for individuals, their
family members, and our society at large. The
authors are correct to advocate for care in
proportion to the prevalence and the damage
associated with eating disorders," he said.
From Medscape
17
New on COPD
GOLD 1 - mild: FEV1 ≥80% predicted. GOLD 2 -
moderate: 50% ≤ FEV1 <80% predicted. GOLD 3 -
severe: 30% ≤ FEV1 <50% predicted.
The first-line treatment in group E chronic
obstructive pulmonary disease is an inhaled
combination of a long-acting muscarinic
antagonist and a long-acting beta-agonist.
This patient’s symptoms and exacerbation
history are consistent with group E chronic
obstructive pulmonary disease (COPD)
according to the latest Global Initiative for
Chronic Obstructive Lung Disease (GOLD)
classification system. Group E COPD, which is a
combination of the two groups formerly
referred to as C and D, is defined by a history of
at least two moderate exacerbations or at least
one exacerbation requiring hospitalization. The
grouping is used to determine initial
pharmacologic treatment, as shown below.
Initial Pharmacologic Treatment for COPD
mMRC 0–1 or CAT <10
mMRC ≥2 or CAT ≥10
≤1 moderate exacerbation
(not leading to hospitalization)
Group A
A bronchodilator
Group B
LABA + LAMA*
≥2 moderate exacerbations or ≥1
Group E**
LABA + LAMA*
exacerbation
hospitalization
requiring
(consider LABA + LAMA + ICS* if the blood
)
3
eosinophil count is ≥300 per mm
mMRC=Modified Medical Research Council;
CAT=COPD Assessment Test; LABA=long-acting
beta-agonist; LAMA=long-acting muscarinic
antagonist; ICS=inhaled glucocorticoids
* Single therapy may be more convenient and
effective than multiple inhalers
** Group E is a combination of the two groups
formerly referred to as C and D
For patients with group E COPD, as in this case,
the preferred initial pharmacologic therapy is an
inhaled combination of a long-acting
muscarinic antagonist (LAMA) and a long-acting
beta-agonist (LABA), such as umeclidinium and
vilanterol. This is a new recommendation in the
GOLD 2023 guidelines based on a Cochrane
systematic review and meta-analysis that
showed fewer exacerbations with combined
therapy than with either agent alone.
An inhaled LABA or LAMA may be considered
as initial long-acting bronchodilator therapy in
patients with GOLD group A COPD (minimal
symptoms and 0 to 1 moderate exacerbations
not requiring hospitalization).
Emerging data suggest that blood eosinophil
counts can predict the magnitude of response to
inhaled glucocorticoids, with counts ≥300 per
mm 3 suggesting responsiveness and counts <100
per mm 3 suggesting a low likelihood of benefit.
In patients with group E COPD and a blood
3
eosinophil count ≥300 per mm , initial therapy
with a LABA–LAMA–inhaled glucocorticoid
combination may be considered. This patient’s
3
eosinophil count is <100 per mm , so an inhaled
glucocorticoid is not indicated.
Inhaled bronchodilators are preferred to oral
bronchodilators, such as theophylline.
Theophylline is not recommended unless other
bronchodilators for long-term treatment are
unavailable or unaffordable.
Last reviewed Dec 2022.
18
Evolution of Management of Acute Myocardial Infarction
The global burden of cardiovascular disease
(CVD) and particularly ischemic heart disease
(IHD) or coronary artery disease (CAD) is huge.
A recent WHO report estimated 17.9 million
global CVD deaths per year. IHD and strokes
constituted 85% of CVD mortality ie. 15 million
per year. Asian Indians and South Asians have
been proven to have a much higher incidence
and severity of CAD and Acute Myocardial
Infarction (AMI). Some studies claim a 10 times
higher incidence than in Caucasians. If one goes
by the statistics in India, the crude death rate in
India was 9.1 per 1000 population (translating to
13 million deaths) in 2022. A 2017 Cardiological
Society of India (CSI) study estimated that 3
million patients in India had ST elevation
Myocardial Infarction (STEMI) and 4 million
had non-ST elevation Myocardial Infarction
(NSTEMI) that year. 1.2 million of STEMI
patients (40%) received thrombolytic therapy
and a mere 53000 underwent primary
percutaneous coronary intervention (PCI) or
primary angioplasty. 30 million people in India
are estimated to have CAD.
Having stated the obvious that AMI is a deadly
killer; let me now go through the evolution of its
treatment in the last 60 odd years. At least some
of us would remember the management of AMI
prior to 1960’s – sedation, oxygen, bed rest and
ineffective or potentially harmful drugs apart
from watchful expectancy being the order of the
day. In hospital and 30 day mortality a er AMI
was 30% up till 1960. This did not include the
number of patients with AMI who did not or
could not reach hospital within the golden
hour/hours, estimated to be at least 25% of
patients who sustain an AMI.
The advent of CCUs and particularly
defibrillation in the early 1960s in the developed
world and possibly at least a decade later in our
country did halve the hospital mortality from
30% to 15%. Mortality at 1 month to 1 year a er
an AMI has remained at 10-12% (slightly higher
in NSTEMI than STEMI). 40% of deaths were
attributable to heart failure. This situation
endured till the late 1980s. How the
management of AMI transformed therea er is a
very fascinating story.
At the 1912 meeting of the Association of
American Physicians, James B Herrick presented
a seminal paper titled “Clinical features of
sudden obstruction of coronary arteries “ in
which he described an autopsy – “ a short
distance from its origin , the le coronary
artery was completely obstructed by a red
thrombus that had formed at a point of great
narrowing… ” Though no one gave it any
importance then, it is considered a classic now.
Herrick’s medical observations at the bedside
and his ability to correlate them with autopsy
findings were truly revolutionary for its time.
Evolution of Thrombolysis
The seeds for the potential of thrombolysis in
AMI had been shown by JB Herrick, but the
means to lyse clot were not available. That some
strains of streptococci could induce fibrinolysis
in human plasma clots had been known for
decades. The first use of thrombolytic therapy
(TLT) in patients with AMI was reported by
Fletcher et al in 1958. In the 1960s and 70s, 24
trials evaluating the efficacy of IV streptokinase
(STK ) were conducted. However due to faulty
trial design and use of a very low dose of STK,
efficacy could not be established and led to the
abandonment of this mode of treatment. TLT in
AMI received renewed attention a er K. Peter
Rentrop published his results in Circulation 1985
on the efficacy of intracoronary STK in
recanalizing 75% of acutely occluded vessels in
AMI. The overall effect on outcomes was still
mixed and skepticism continued.
The publication of the GISSI trial from Italy in
1986 was what finally and definitely signalled the
dawn of a new era for more effective treatment
of AMI. 11,712 patients were randomized to
receive either standard care or 1.5 million units
of STK IV. 21-day mortality in patients receiving
standard care was 13% Vs. 10.7% in those who
received STK with a highly significant 18%
relative risk reduction. At 12 months also total
mortality was significantly lower- 17.2% for STK
19
group Vs. 19% for standard care group.
Thrombolytic treatment (TLT) prevents 30 early
deaths per 1000 patients if given within 6 hours.
Primary Percutaneous Coronary Intervention
(Primary PCI) or Primary Angioplasty in
Myocardial Infarction (PAMI)
This journey began in the early 1980s, in fact
before the validation of IV TLT in AMI.
Geoffrey O Hartzler of Kansas City USA
published his experience of treating 41 patients
with AMI with Primary PCI in 1983. This was
thought to be highly controversial by most of
the Cardiological community at that time given
that new thrombolytic therapies were emerging.
Proponents of primary PCI were called ‘savages’
or ‘cowboys’. It took 10 years for Hartzler’s
experimental findings to be confirmed in large
randomized trials.
In March 1993 (30years ago) the first two
randomized controlled trials showing that PAMI
was superior to IV thrombolysis, were published
from USA and Netherlands simultaneously. In
December 1993, Hartzler published his results
with PAMI in 1000 patients. In 1997, a
meta-analysis of the first 10 international trials
highlighted a significant 34% reduction in
30-day mortality with PAMI (4.4%) Vs. IV
thrombolysis (6.5%). It became a CLASS I
recommendation in European Society of
Cardiology guidelines for STEMI only in 2003.
At this juncture, it is pertinent to note that we at
Manipal Hospital, Bangalore started routinely
doing Primary Angioplasty in MI in 1998.
Compared to IV TLT, Primary PCI reduced
mortality by 34%, reinfarction by 64%, and
intracranial hemorrhage by 95% and
cerebrovascular accidents by 53%. Again, as with
TLT, the golden hour /hours a er onset of
symptoms are vital for improving outcomes. A
PCI related delay of 1 hour negates any
mortality benefit compared to immediate TLT.
Pharmaco Invasive Strategy
It consists of immediate /early thrombolysis
followed by CAG/PTCA within 3-24 hours. This
is very relevant in our country where less than
100 cities and about 700 odd Cath labs
nationwide are available to perform Primary
PCI for a 1.4 billion population.
Newer Thrombolytic Agents
GENERATION
FIBRIN
NON-FIBRIN
SPECIFIC
SPECIFIC
Streptokinase
First
Urokinase
Recombinant
Second
Tissue
Pro Urokinase
Plasminogen
Activator
(rTPA)
Third
Alteplase
Tenecteplase
Reteplase &
others
APSAC
Four agents are used in our country –
streptokinase, Alteplase, Reteplase and
Tenecteplase. Each must be reconstituted before
use. STK must be infused over 1 hour. It is the
more suitable for hospital than community care.
Two drugs are body weight dependent –
Tenecteplase which is injected in a single bolus
and Alteplase which must be infused, working
best with accelerated infusion rate. Reteplase is
independent of weight and is injected as a
double bolus 30 minutes apart. Only STK does
not require Heparin as adjunctive therapy for at
least 24 hours to prevent re thrombosis. Patency
rates with the newer fibrin specific
thrombolytics are 10-15% higher than with STK
(60-70%).However costs are about 5 times greater
as well.
Door to Needle time is the time from first
medical contact to start of TLT and ideally is 20
minutes. Door to Balloon time is the time from
first medical contact to first balloon inflation and
is ideally less than 90 minutes. These are terms
used to reconfirm the importance of the golden
hour and to ensure that hospital systems and
standards keep improving constantly.
There are many more aspects of the therapy of
AMI which are beyond the scope of this article.
20
However, current antiplatelet regimes in AMI
are as follows:
choice: Aspirin + Ticagrelor
choice: Aspirin+ Prasugrel
choice: Aspirin + Clopidogrel
1 st
2 nd
3 rd
No other Anti platelet drugs are currently
recommended for use in AMI.
Glycoprotein IIb IIIa inhibitors :
Abciximab intracoronary bolus is still used in
settings where there is a huge clot burden and/
or in acute stent thrombosis. Eptifibatide and
Tirofiban , the other Gp IIb IIIa inhibitors which
were widely used before PAMI patients were
taken into the Cath lab have largely gone out of
use because of the availability of rapidly acting
and powerful oral antiplatelet drugs notably
Ticagrelor.
Adjunctive Clot Busting Methods in PAMI
1. Aspiration thrombectomy – Manual
A double lumen catheter is passed across the
lesion over a 0.014 guide wire. A large lockable
aspiration syringe is attached to the proximal
port and clot aspirated into the syringe by
manual suction. It is recommended in lesions
with thrombus burden, and used in about 1 in 3
PAMIs.
2. Mechanical suction
Using a motorized vacuum pump to aspirate
thrombus from within the coronary artery is
particularly relevant in large coronary arteries
with massive thrombus burden. The most used
devise is called PENUMBRA.
3. Rheolytic thrombectomy- Angiojet / XSizer
Attempts thrombus fragmentation prior to
aspiration, using pressurized heparinized saline
jets to create low pressure zones thus creating a
vacuum effect by which thrombus can be drawn
into the catheter enabling better vessel
reperfusion.
Excimer Laser Coronary Angioplasty [ELCA]
This is a very exciting new tool to deal with
uncrossable /undilatable coronary stenoses as
well as lesions with a large thrombus burden.
EXCIMER is an acronym for EXCIted diMER. It
produces pulsatile and short wavelength
ultraviolet laser energy. The pulsatile nature
ensures precise ablation with minimal thermal
injury. Short wave length reduces depth of
penetration (compared to infrared range of
argon and ND-Yag lasers) used in the 1990s. This
results in less collateral damage. First successful
ELCA on humans was done at Los Angeles, USA
in 1998. It is currently FDA approved for
thrombotic saphenous vein gra lesions but is
also being used (off label) for native coronary
lesions with large thrombus burden.
The modern era, from the mid-1980s till date,
has been a very exciting one in the field of
Interventional Cardiology. I and many like me
have been fortunate to practice cardiology
during this entire period. The evolution of the
management of AMI has been one of the
crowning achievements of modern medicine in
recent times.
References
1. Grines CL, Browne KF, Marco J, et al. A comparison
of immediate angioplasty with thrombolytic therapy
for acute myocardial infarction. N Engl J
Med. 1993; 32: 673–679.
2. Gruppo Italiano per lo Studio della Streptochinasi
nell'Infarto Miocardico (GISSI) Effectiveness of
intravenous thrombolytic treatment in acute
myocardial infarction. Lancet February 22,
1986DOI:https://doi.org/10.1016/S0140-6736(86)9236
8-83.
3.Hartzler GO, Rutherford BD, McConahay DR, et al.
Percutaneous transluminal coronary angioplasty with
and without thrombolytic therapy for treatment of
acute myocardial infarction. Am Heart J 1983;
106:965- 73.
4. Herrick JB. Clinical features of sudden obstruction
of the coronary arteries. JAMA. 1912;59:2015–20.
5. Keeley EC, Boura JA, Grines CL. Comparison of
primary angioplasty and intravenous thrombolytic
therapy for acute myocardial infarction: a
21
quantitative review of 23 randomized
trials. Lancet. 2003; 361: 13–20.
6. National interventional council data for the year
2018-India Sreenivas Kumar Arramraju, a,∗ Rama
Krishna Janapati, b E. Sanjeeva Kumar, b and Gokul
Reddy Mandala b Indian Heart J. 2020 Sep-Oct; 72(5):
351–355.
7. Nour Tashtish, 1 Tarek Chami, 1 Tony Dong, 2 Besher
Chami, 3 Sadeer Al-Kindi, 1 Haytham Mously, 1 Scott
Janus, 1 Tarek Hammad, 1 Mehdi H.
Shishehbor, 1 and Anjan Gupta
1 Routine Use of the
“Penumbra” Thrombectomy Device in Myocardial
Infarction: A Real-World Experience—ROPUST
Study J Interv Cardiol. 2022; 2022: 5692964
8. O'Neill WW, Timmis GC, Bourdillon P, et al. A
prospective randomized clinical trial of
intracoronary streptokinase versus coronary
Miscellany
Every festival has its own message. Here is one
very relevant.
Dickens’ Christmas Carol
Many of you will know of Charles Dickens great
Christmas novella, “A Christmas Carol”. It has
been suggested that Dickens’ story reshaped the
image of Christmas worldwide, reinvigorating a
festival which had its origins in pre-Christian
times. The message of Christmas transcends
cultures and beliefs around the world,
promoting the message of goodwill, peace, and
harmony. If only that message could somehow
help bring peace to our troubled world and the
awful military conflicts, the impacts of climate
change and the widening inequality gap
between the rich and the poor.
In the book, Tiny Tim is the young, ailing son of
Bob Cratchit, Ebenezar Scrooge’s underpaid
clerk. Tim walks with a crutch and has 'his limbs
supported by an iron frame'. Despite his
physical difficulties, he is a positive and
generous child. He thinks of others and is
well-loved by his family. When visited by the
“Ghost of Christmas Present,” Scrooge is shown
just how ill the boy really is (the family cannot
afford to provide adequate care for him on the
angioplasty for acute myocardial infarction. N Engl J
Med 1986;314:812-8.
9. Protty MB, Hussain HI, Gallagher S, Al-Raisi S,
Aldalati O, Farooq V, Sharp ASP, Egred M, O’Kane P,
Ludman P, et al. Excimer laser coronary atherectomy
during complex PCI: an analysis of 1,471 laser cases
from the British Cardiovascular Intervention Society
database. Catheter Cardiovasc Interv. 2020;
97:E911–E918.
10. Rentrop P. Thrombolytic therapy in patients with
acute myocardial infarction. Circulation. 1985; Vol 71,
No 4, April:627-631.
Dr Padmakumar
Padmakumar1956@gmail.com
salary that Scrooge pays Cratchit. When visited
by the Ghost of ”Christmas Yet to Come,”
Scrooge sees that Tiny Tim has died. This, and
several other visions, led Scrooge to reform his
ways. At the end of the story, Dickens makes it
explicit that Tiny Tim does not die, and Scrooge
becomes a "second father" to him.
Tiny Tim’s literary role in the story is to
generate compassion and humanity in the old
miser, Scrooge. Dickens uses Tiny Tim to
represent the mass of poor children living in
misery and need. He uses Tiny Tim to show the
readers how vulnerable the poor are; there is no
money for medical treatment and so Tiny Tim
must needlessly die.
We also ask ourselves what disease did Tiny
Tima suffer from? There is a large body of
medical literature out there, trying to answer the
question. I thought that I would draw your
attention to paper in JAMA from 2012
The above message is from Dr John
Wynn-Jones, a fine rural physician, and
ex-president of WONCA rural.
22
Welcome to AFPI Karnataka
http://www.afpikarnataka.org
THIS SPACE IS OPEN FOR ADVERTISEMENTS
23